Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Quaker BioVentures is a venture capital firm investing in life science companies. The firm leads investments across the spectrum of the life science industry, including biopharmaceuticals, medical devices, human diagnostics, specialty pharmaceuticals, and healthcare services. Quaker BioVentures invests in companies at all stages of development, from early stage start-ups to public companies. Founded in 2003, the firm is currently investing Quaker BioVentures II, a $420 million fund formed in 2007. Quaker BioVentures manages over $700 million in committed capital.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
9/2012 | Intact Vascular | Series A | 15.5M |
10/2008 | Biolex Therapeutics | Series D | 0 |
6/2007 | Argolyn Bioscience | Series A | 15.8M |
10/2009 | Neuronetics | Series D | 0 |
8/2003 | Biolex Therapeutics | Venture Round | 0 |
10/2008 | Corridor Pharmaceuticals | Seed Round | 0 |
5/2005 | Celator Pharmaceuticals | Series B | 20M |
12/2009 | Regado Biosciences | Series D | 0 |
1/2011 | TetraLogic Pharmaceuticals | Series C | 0 |
3/2006 | Nitric Bio | Series A | 14M |
12/2002 | BioRexis | Series A | 8M |
11/2008 | Tengion | Series C | 0 |
3/2007 | Regado Biosciences | Series C | 23M |
4/2013 | RainDance Technologies | Series E | 0 |
3/2004 | BioRexis | Series B | 30M |
6/2006 | TetraLogic Pharmaceuticals | Series B | 36M |
6/2011 | NovaSom | Series D | 35M |
4/2004 | MedMark Treatment Centers | Venture Round | 28M |
3/2006 | Helomics | Venture Round | 20M |
6/2010 | Helomics | Series D | 33M |
8/2009 | Rapid Micro Biosystems | Series A | 18.6M |
2/2005 | Neotropix | Series A | 10M |
1/2010 | Tarsa Therapeutics | Series A | 24M |
9/2013 | PreCision Dermatology | Debt Financing | 67M |
3/2008 | EKR Therapeutics | Series D | 50M |
7/2008 | Celator Pharmaceuticals | Series C | 22.5M |
6/2006 | Tengion | Series B | 50M |
8/2007 | Celator Pharmaceuticals | Series C | 10M |
9/2010 | Celator Pharmaceuticals | Series D | 0 |
10/2007 | Tengion | Series C | 33M |
1/2010 | BioLeap | Series A | 5M |
5/2010 | TearScience | Series C | 44.5M |
4/2005 | TargetRx | Series D | 0 |
9/2005 | Amicus Therapeutics | Series C | 55M |
6/2004 | Nucleonics | Series B | 49.2M |
6/2009 | Cempra | Series C | 46M |
8/2010 | TetraLogic Pharmaceuticals | Series C | 0 |
9/2005 | Biolex Therapeutics | Series B | 36M |
5/2011 | Neuronetics | Series E | 30M |
6/2010 | Corridor Pharmaceuticals | Series A | 0 |
5/2007 | Biolex Therapeutics | Series C | 30M |
3/2012 | Tarsa Therapeutics | Series B | 28M |
9/2006 | Amicus Therapeutics | Series D | 60M |
4/2015 | Neuronetics | Series F | 0 |
7/2008 | NuPathe | Series B | 30M |
4/2008 | Transave | Series D | 35M |
10/2009 | Asensus Surgical | Post-IPO Equity | 0 |
3/2019 | Kaarta | Series A | 0 |
11/2008 | Helomics | Venture Round | 43M |
5/2005 | Tranzyme | Series A | - |
4/2008 | Diasome Pharmaceuticals | Series B | 8.4M |
4/2007 | StageMark | Series B | 1.6M |
8/2007 | EKR Therapeutics | Series C | 13M |
11/2007 | Tranzyme | Venture Round | 20M |
10/2009 | Sleep Solutions | Series F | 20M |
8/2010 | Achillion Pharmaceuticals | Post-IPO Equity | 50.1M |
10/2007 | Optherion | Series A | 37M |
1/2011 | RainDance Technologies | Series D | 37.5M |
3/2019 | Kaarta | Series A | 0 |
4/2015 | Neuronetics | Series F | 0 |
9/2013 | PreCision Dermatology | Debt Financing | 0 |
4/2013 | RainDance Technologies | Series E | 0 |
9/2012 | Intact Vascular | Series A | 0 |
3/2012 | Tarsa Therapeutics | Series B | 0 |
6/2011 | NovaSom | Series D | 0 |
5/2011 | Neuronetics | Series E | 0 |
1/2011 | RainDance Technologies | Series D | 0 |
1/2011 | TetraLogic Pharmaceuticals | Series C | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|